Therapeutic duplication would be a concern for a patient prescribed both tamsulosin and:

Rationale

Therapeutic duplication would be a concern for a patient prescribed both tamsulosin and doxazosin.

Both tamsulosin and doxazosin are alpha-1 adrenergic antagonists used to treat benign prostatic hyperplasia (BPH) and can lead to similar therapeutic effects. Prescribing both medications increases the risk of adverse effects such as hypotension and dizziness due to their overlapping mechanisms of action.

A (doxazosin) CORRECT

Tamsulosin and doxazosin belong to the same class of medications, specifically alpha-1 blockers, which are used to manage urinary symptoms associated with BPH. Using both concurrently can result in therapeutic duplication, heightening the risk of side effects like low blood pressure and fainting, making this combination particularly concerning in clinical practice.

B (guaifenesin) YOUR ANSWER

Guaifenesin is an expectorant used to relieve chest congestion by thinning mucus, with no overlap in therapeutic use with tamsulosin. Since guaifenesin does not share similar pharmacological effects or indications, it does not pose a concern for therapeutic duplication with tamsulosin.

C (tamoxifen) YOUR ANSWER

Tamoxifen is a selective estrogen receptor modulator primarily used in breast cancer treatment, with no direct relation to the action of tamsulosin. The lack of shared therapeutic indications means that there is no risk of therapeutic duplication when these two medications are prescribed together.

D (baclofen) YOUR ANSWER

Baclofen is a muscle relaxant used to treat spasticity. It functions through a different mechanism than tamsulosin and does not overlap in therapeutic effect. Therefore, it does not present a concern for therapeutic duplication when used in conjunction with tamsulosin.

Conclusion

Therapeutic duplication arises when two medications with similar effects are prescribed together, which can amplify potential side effects and complicate patient management. In the case of tamsulosin and doxazosin, both are alpha-1 adrenergic antagonists targeting similar symptoms of BPH, leading to safety concerns. Other options listed, such as guaifenesin, tamoxifen, and baclofen, do not share therapeutic pathways with tamsulosin, thus avoiding the risk of duplication.

Therapeutic duplication would be a concern for a patient prescribed both tamsulosin and:

Therapeutic duplication would be a concern for a patient prescribed both tamsulosin and doxazosin.

Related Questions

Related Quizzes

How familiar were you with this question?

Report an Issue

Rate this Practice Test